A Clinical Trial to Investigate the Efficacy of a Supplement to Improve and Maintain Cognitive Function and Memory

N/AActive Not RecruitingNCT06523218

Scale Media Inc50 enrolled

Overview

This study will evaluate the efficacy of 1MD Nutrition's MindMD supplement in improving and maintaining cognitive function and memory. The randomized controlled trial will include 50 healthy participants aged 50-75 years, lasting for 3 months. Participants will be randomized to receive either the test product or a placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Cognitive Decline Cognitive Function

Interventions

MindMD SupplementDIETARY_SUPPLEMENT

Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.

PlaceboOTHER

Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.

Eligibility

Sex: ALLMin age: 50 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 50-75 years * Regular experience of symptoms related to cognitive decline (e.g., forgetfulness, lack of focus, brain fog) * Generally healthy without uncontrolled chronic diseases * Willingness to avoid certain medications and supplements during the study Exclusion Criteria: * Any medical condition or treatment impacting cognitive ability Mental health or neurological disorders * Severe allergies, particularly to soy or other product ingredients * Taking blood thinning medication * Recent or planned surgeries * Major illness in the past three months

Locations (1)

Citruslabs

Santa Monica, California, United States

Outcomes

Primary Outcomes

Cognitive Function and Memory Improvement

Measurement of cognitive function and memory through Cognitive Battery Testing. The Cognitive Battery Testing includes assessments such as Polygons, Double Trouble, Feature Match, Paired Associates, Digit Span, and Spatial Planning. These assessments provide objective measurements of various cognitive functions, including processing speed, memory recall, selective attention, and executive function.

Time frame: Baseline, Month 2, and Month 3

Secondary Outcomes

Participants' Perceptions of Cognitive Function and Memory using the Cognitive Function Questionnaire

Evaluation of participants' self-reported perceptions of the effect of the MindMD supplement on cognitive function and memory. This includes aspects such as focus and attentiveness, comprehension and mental clarity, learning acuity, absentmindedness, and overall quality of life. These perceptions will be measured through the Cognitive Function Questionnaire (CFQ) at specified time points: Baseline (Day 0), Month 1, Month 2, and Month 3.

Time frame: Baseline, Month 1, Month 2, and Month 3

Participants' Quality of Life

Assessment of participants' quality of life using the WHO-5 Well-Being Index. These assessments will be conducted at Baseline (Day 0), Month 1, Month 2, and Month 3.

Time frame: Baseline, Month 1, Month 2, and Month 3

Participants' Focus and Attentiveness

Evaluation of participants' focus and attentiveness using the Visual Analog Scale (VAS). These assessments will be conducted at Baseline (Day 0), Month 1, Month 2, and Month 3.

Time frame: Baseline, Month 1, Month 2, and Month 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.